Weiqida was also found in contempt of the Delhi High Court’s original preliminary injunction order granted in April 2017, through its continued importation and sale of its amoxicillin trihydrate active pharmaceutical ingredient (API) in India.
Centrient will seek monetary compensation for the damage sustained by the illegal shipments, in violation of the preliminary injunction since April 2017.
It wishes to put all buyers of Weiqida’s amoxicillin trihydrate API in India on notice (even if such API transits through India under advanced licence) to be aware of the above orders of the Delhi High Court.
Centrient shall ensure full compliance of the orders of the court and will notify the Indian Customs Authority and other authorities to seize all future Weiqida amoxicillin shipments at the relevant customs facilities.
Centrient Chief Executive Officer, Karl Rotthier said Centrient held world-class intellectual property portfolio relating to its innovative, sustainable and environmentally-friendly amoxicillin technology.
“We will continue to rigorously defend our Intellectual Property assets worldwide as we continue to invest in our innovative R&D programmes directed to enzymatically produce, sustainable antimicrobials and statins,” he said.
Centrient, the leading manufacturer of beta-lactam antibiotics and provider of next generation statins and anti-fungals, is headquartered in Rotterdam, the Netherlands. More details at www.centrient.com
-- BERNAMA
No comments:
Post a Comment